Detecting early stage lung adenocarcinoma using imaging and biopsy markers
Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinoma
This study is looking to help doctors find early signs of lung adenocarcinoma more accurately by using special imaging and genetic information from biopsies, so they can better understand how aggressive the tumors are and create more personalized treatment plans for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10885188 on NIH RePORTER |
What this research studies
This research aims to improve the detection of early stage lung adenocarcinoma by integrating advanced imaging techniques with molecular markers derived from biopsies. The approach focuses on identifying whether tumors are aggressive or indolent before surgical intervention, which could help tailor treatment plans more effectively. By developing and validating a model that combines radiomic and gene expression biomarkers, the research seeks to provide more accurate predictions of tumor behavior using limited tissue samples. This could lead to better management of lung cancer and reduce unnecessary treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early stage lung adenocarcinoma who are scheduled for surgical treatment.
Not a fit: Patients with advanced lung cancer or those who are not candidates for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for lung cancer patients, improving outcomes and reducing unnecessary procedures.
How similar studies have performed: Previous research has shown promise in using imaging and molecular markers for cancer detection, suggesting that this integrated approach could be effective.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Lenburg, Marc Elliott — Boston University Medical Campus
- Study coordinator: Lenburg, Marc Elliott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.